EGFR第一/二代酪氨酸激酶抑制剂获得性耐药机制
该综述聚焦EGFR突变非小细胞肺癌(NSCLC)对第一、二代EGFR酪氨酸激酶抑制剂(TKI)的获得性耐药机制。约60%耐药患者出现T790M突变,该突变改变药物结合与突变EGFR酶活性;其他机制包括MET扩增、ERBB2扩增及小细胞肺癌转化等。文章汇总耐药机制、近期临床试验结果及克服耐药的新策略。
要点
- 约60%的EGFR TKI获得性耐药由T790M突变介导。
- T790M改变药物结合并影响突变EGFR的酶活性。
- 其他耐药机制包括MET扩增、ERBB2扩增和小细胞肺癌转化。
核心结论
- EGFR突变NSCLC患者对第一、二代EGFR TKI的获得性耐药机制已被部分阐明,约60%为T790M突变。
研究设计与样本
- 本文为文献综述,聚焦EGFR突变NSCLC的获得性耐药机制、近期临床试验结果及克服耐药的新策略。
主要发现
- 约60%对厄洛替尼、吉非替尼和阿法替尼获得性耐药的患者出现药物靶点内新突变T790M。
- T790M已被证实可改变药物结合及突变EGF受体的酶活性。
- 较少见的获得性耐药机制包括MET扩增、ERBB2扩增和小细胞肺癌转化等。
临床怎么用
- 对第一、二代EGFR TKI获得性耐药应识别T790M及其他耐药机制,以指导合理后续治疗策略。
局限性
- 本文为叙述性综述,未报告系统检索范围或定量合并分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating mutations within the epidermal growth factor receptor (EGFR) frequently derive significant clinical and radiographic benefits from treatment with EGFR tyrosine kinase inhibitors (TKIs). As such, prospective identification of EGFR mutations is now the standard of care worldwide. However, acquired therapeutic resistance to these agents invariably develops. Over the past 10 years, great strides have been made in defining the molecular mechanisms of EGFR TKI resistance in an effort to design rational strategies to overcome this acquired drug resistance. Approximately 60% of patients with acquired resistance to the EGFR TKIs (erlotinib, gefitinib, and afatinib) develop a new mutation within the drug target. This mutation-T790M-has been shown to alter drug binding and enzymatic activity of the mutant EGF receptor. Less common mechanisms of acquired resistance include MET amplification, ERBB2 amplification, transformation to small-cell lung cancer, and others. Here, we present a condensed overview of the literature on EGFR-mutant NSCLC, paying particular attention to mechanisms of drug resistance, recent clinical trial results, and novel strategies for identifying and confronting drug resistance, while also striving to identify gaps in current knowledge. These advances are rapidly altering the treatment landscape for EGFR-mutant NSCLC, expanding the armamentarium of available therapies to maximize patient benefit.
引用
- Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018. PMID: 29462254. doi:10.1093/annonc/mdx703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。